Embecta Corp. (NASDAQ: EMBC) Investor Alert: Deadline in Lawsuit on August 17, 2026

A deadline is coming up on August 17, 2026 in the lawsuit filed for certain investors of Embecta Corp. (NASDAQ: EMBC) over alleged securities laws violations by Embecta Corp.

Investors who purchased shares of Embecta Corp. (NASDAQ: EMBC) have certain options and there are strict and short deadlines running. Deadline: August 17, 2026. NASDAQ: EMBC stockholders should contact the Shareholders Foundation at mail@shareholdersfoundation.com or call +1(858) 779 - 1554.

Parsippany, NJ based Embecta Corp., a medical device company, provides solutions to improve the health and wellbeing of people living with diabetes in the United States and internationally. Embecta Corp. (NASDAQ: EMBC) reported that its Total Revenue declined from over $1.12 billion for the 12 months period that ended on September 30, 2024, to over $1.08 billion for the 12 months period that ended on September 30, 2025, and that its Net Income over those respective time periods increased from $78.3 million to $95.4 million.

On May 5, 2026, Embecta announced its second quarter 2026 financial results, allegedly disclosing that Embecta missed its guidance for the second quarter and lowered its guidance for the 2026 fiscal year. Specifically, the Embecta class action lawsuit alleges that Embecta's revenue declined over 14%, much higher than the guidance of flat to a decline of 2% and that Embecta was lowering estimates on U.S. performance, largely in part due to weakness in its pen needle sales. On this news, the price of Embecta stock decline nearly 58%, according to the complaint.

Shares of Embecta Corp. (NASDAQ: EMBC) declined from $14.78 per share on November 25, 2025, to as low as $3.01 per share on June 23, 2026.

According to the complaint filed in the U.S. District Court for the District of New Jersey the plaintiff alleges on behalf of purchasers of Embecta Corp. (NASDAQ: EMBC) common shares between November 25, 2025 and May 4, 2026, that the defendants violated Federal Securities Laws. More specifically, the plaintiff claims that between November 25, 2025 and May 4, 2026, the defendants made false and/or misleading statements and/or failed to disclose that the defendants created the false impression that Embecta was providing accurate and reliable fiscal guidance for second quarter and full year 2026, and that Embecta knew or recklessly disregarded that segment weakness, especially in the United States pen needle market, was likely to disrupt Embecta's original revenue guidance and second quarter 2026 results.

Those who purchased shares of Embecta Corp. (NASDAQ: EMBC) have certain options and should contact the Shareholders Foundation.

Contact:
Michael Daniels
Shareholders Foundation, Inc.
3111 Camino Del Rio North
Suite 423
San Diego, CA 92108
Tel: +1-(858)-779-1554
E-Mail: mail@shareholdersfoundation.com

About Shareholders Foundation, Inc.
The Shareholders Foundation, Inc. is a professional portfolio monitoring and settlement claim filing service, and an investor advocacy group, which does research related to shareholder issues and informs investors of securities lawsuits, settlements, judgments, and other legal related news to the stock/financial market. Shareholders Foundation, Inc. is in contact with a large number of shareholders and offers help, support, and assistance for every shareholder. The Shareholders Foundation, Inc. is not a law firm. Referenced cases, investigations, and/or settlements are not filed/initiated/reached and/or are not related to Shareholders Foundation. The information is provided as a public service. It is not intended as legal advice and should not be relied upon.

This release was published on openPR.